Stock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement

Stock Track03-03

Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.

The biotech company entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock, according to an SEC filing. Such equity financing arrangements often lead to investor concerns over potential dilution of existing shareholders' stakes.

The move comes despite positive regulatory news earlier in the day regarding the removal of a clinical hold on a key gene therapy trial. The market's reaction to the financing announcement appears to have overshadowed the earlier development, driving the stock lower after the closing bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182401360?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 10:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182401360","market":"hk","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement","media":"Stock Track","content":"<p>Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.</p><p>The biotech company entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock, according to an SEC filing. Such equity financing arrangements often lead to investor concerns over potential dilution of existing shareholders' stakes.</p><p>The move comes despite positive regulatory news earlier in the day regarding the removal of a clinical hold on a key gene therapy trial. The market's reaction to the financing announcement appears to have overshadowed the earlier development, driving the stock lower after the closing bell.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-03 10:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.</p><p>The biotech company entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock, according to an SEC filing. Such equity financing arrangements often lead to investor concerns over potential dilution of existing shareholders' stakes.</p><p>The move comes despite positive regulatory news earlier in the day regarding the removal of a clinical hold on a key gene therapy trial. The market's reaction to the financing announcement appears to have overshadowed the earlier development, driving the stock lower after the closing bell.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1182401360","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182401360","pubTimestamp":1772506245,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.The biotech company entered into a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"个股追踪|4亿美元出售协议Intellia Therapeutics盘后暴跌5.83%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.The biotech company entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock, according to an SEC filing. Such equity financing arrangements often lead to investor concerns over potential dilution of existing shareholders' stakes.The move comes despite positive regulatory news earlier in the day regarding the removal of a clinical hold on a key gene therapy trial. The market's reaction to the financing announcement appears to have overshadowed the earlier development, driving the stock lower after the closing bell.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182401360","isCrawlerRequest":true}